SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation

Jetske Ruiterkamp, Adri C Voogd, Vivianne C G Tjan-Heijnen, Koop Bosscha, Yvette M van der Linden, Emiel J Th Rutgers, Epie Boven, Maurice J C van der Sangen, Miranda F Ernst, Dutch Breast Cancer Trialists' Group (BOOG), Jetske Ruiterkamp, Adri C Voogd, Vivianne C G Tjan-Heijnen, Koop Bosscha, Yvette M van der Linden, Emiel J Th Rutgers, Epie Boven, Maurice J C van der Sangen, Miranda F Ernst, Dutch Breast Cancer Trialists' Group (BOOG)

Abstract

Background: Five percent of all patients with breast cancer have distant metastatic disease at initial presentation. Because metastatic breast cancer is considered to be an incurable disease, it is generally treated with a palliative intent. Recent non-randomized studies have demonstrated that (complete) resection of the primary tumor is associated with a significant improvement of the survival of patients with primary metastatic breast cancer. However, other studies have suggested that the claimed survival benefit by surgery may be caused by selection bias. Therefore, a randomized controlled trial will be performed to assess whether breast surgery in patients with primary distant metastatic breast cancer will improve the prognosis.

Design: Randomization will take place after the diagnosis of primary distant metastatic breast cancer. Patients will either be randomized to up front surgery of the breast tumor followed by systemic therapy or to systemic therapy, followed by delayed local treatment of the breast tumor if clinically indicated.Patients with primary distant metastatic breast cancer, with no prior treatment of the breast cancer, who are 18 years or older and fit enough to undergo surgery and systemic therapy are eligible. Important exclusion criteria are: prior invasive breast cancer, surgical treatment or radiotherapy of this breast tumor before randomization, irresectable T4 tumor and synchronous bilateral breast cancer. The primary endpoint is 2-year survival. Quality of life and local tumor control are among the secondary endpoints.Based on the results of prior research it was calculated that 258 patients are needed in each treatment arm, assuming a power of 80%. Total accrual time is expected to take 60 months. An interim analysis will be performed to assess any clinically significant safety concerns and to determine whether there is evidence that up front surgery is clinically or statistically inferior to systemic therapy with respect to the primary endpoint.

Discussion: The SUBMIT study is a randomized controlled trial that will provide evidence on whether or not surgery of the primary tumor in breast cancer patients with metastatic disease at initial presentation results in an improved survival.

Trial registration: NCT01392586.

Figures

Figure 1
Figure 1
Pooled analyses of hazard ratios for overall mortality for surgery versus no surgery for patients with stage IV breast cancer [14]. (1): patients with free surgical margins; (2): patients with positive surgical margins.
Figure 2
Figure 2
Study design.

References

    1. Ruiterkamp J, Ernst MF, de Munck L, van der Heiden-van de Loo M, Bastiaannet E, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VCG, Voogd AC. Improved survival of patients with primary distant metastatic breast cancer in the period of 1995-2008. A nationwide population-based study in the Netherlands. Breast Cancer Res Treat. 2011;128:495–503. doi: 10.1007/s10549-011-1349-x.
    1. Ly BH, Nguyen NP, Vinh-Hung V, Rapiti E, Vlastos G. Loco-regional treatment in metastatic breast cancer patients: Is there a survival benefit? Breast Cancer Res Treat. 2010;119:537–545. doi: 10.1007/s10549-009-0610-z.
    1. Chia SK, Speers CH, D'yachkova Y. et al.The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer. 2007;110:973–979. doi: 10.1002/cncr.22867.
    1. Ernst MF, van de Poll-Franse LV, Roukema JA. et al.Trends in the prognosis of patients with primary metastatic breast cancer diagnosed between 1975 and 2002. Breast. 2002;16:344–351.
    1. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery. 2002;132:620–627. doi: 10.1067/msy.2002.127544.
    1. Babiera GV, Rao R, Feng L. et al.Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol. 2005;13:776–782.
    1. Rapiti E, Verkooijen HM, Vlastos G. et al.Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743–2749. doi: 10.1200/JCO.2005.04.2226.
    1. Fields RC, Donna BJ, Trinkaus K. et al.Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol. 2007;14(12):3345–3351. doi: 10.1245/s10434-007-9527-0.
    1. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer. Analysis of the 1988-2003 SEER data. Ann Surg Oncol. 2007;14(8):2187–2194. doi: 10.1245/s10434-007-9438-0.
    1. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM. Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg. 2008;247(5):732–738. doi: 10.1097/SLA.0b013e3181656d32.
    1. Ruiterkamp J, Ernst MF, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC. Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol. 2009;35:1146–1151. doi: 10.1016/j.ejso.2009.03.012.
    1. Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M, King TA. Stage IV breast cancer in the era of targeted therapy. Does surgery of the primary tumor matter? Cancer. 2010;116(5):1226–1233. doi: 10.1002/cncr.24873.
    1. Rao R, Feng L, Kuerer HM. et al.Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol. 2008;15:1696–1702. doi: 10.1245/s10434-008-9830-4.
    1. Ruiterkamp J, Voogd AC, Bosscha K, Tjan-Heijnen VCG, Ernst MF. Impact of breast surgery on survival in patients with distant metastases at initial presentation. A systematic review of the literature. Breast Cancer Res Treat. 2010;120(1):9–16. doi: 10.1007/s10549-009-0670-0.
    1. Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol. 2008;15:3384–3395. doi: 10.1245/s10434-008-0085-x.
    1. Bafford AC, Burstein HJ, Barkley CR, Smith BL, Lipsitz S, Iglehart JD, Winer EP, Golshan M. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009;115:7–12. doi: 10.1007/s10549-008-0101-7.
    1. Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD. Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res. 2010;161(1):83–88. doi: 10.1016/j.jss.2008.12.030.
    1. Dominici L, Najita J, Hughes M, Niland J, Marcom P, Wong Y, Carter B, Javid S, Edge S, Burstein H, Golshan Mehra. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011. in press .
    1. Pocock S, Simon R. Sequential treatment assignment with balancing of prognostic factors in controlled clinical trials. Biometrics. 1975;31:103–115. doi: 10.2307/2529712.
    1. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol. 1971;44:793–797. doi: 10.1259/0007-1285-44-526-793.
    1. Peto R, Pike MC, Armitage P. et al.Design and analysis of randomized clinical trials requiring prolonged observation or each patient. Br J Cancer. 1976;34:585–612. doi: 10.1038/bjc.1976.220.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe